Lupin Nagpur plant gets satisfactory USFDA rating
Lupin receives a Voluntary Action Indicated (VAI) classification from the USFDA for its Nagpur injectables facility after a September 2025 inspection. Read the full details.
Lupin receives a Voluntary Action Indicated (VAI) classification from the USFDA for its Nagpur injectables facility after a September 2025 inspection. Read the full details.
Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.
Discover how Lupin's #livebeyondepilepsy initiative, with 500+ neurologists, is transforming epilepsy care and combating stigma for 14 million affected Indians. Join the movement.
Investors brace for a high-stakes earnings Thursday as insurance giant LIC, EV pioneer Ola Electric, and pharma major Lupin headline over 20 companies declaring Q2 FY2025 results. Get expert insights on what to expect.